Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Elixirgen Therapeutics is raising $5,706,889.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Akihiro Ko played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elixirgen Therapeutics

Elixirgen Therapeutics, Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines. The company is focused on curing humanity’s ailments through innovations in stem cell biology. The company’s experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics’ scientists to conduct research at state-of-the-art facilities.

To learn more about Elixirgen Therapeutics, visit http://elixirgentherapeutics.com/

Contact:
Akihiro Ko, Chief Executive Officer
443-869-5420
https://www.linkedin.com/in/akihiro-ko-2a67404b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved